NSCLC

This study tests a new drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 adults will take part.

This study tests whether using a tool called OncoChoice to select chemotherapy can help people with advanced non-small cell lung cancer (NSCLC) that has spread. About 29 adults who have already tried at least one other treatment will receive chemotherapy chosen by OncoChoice. The…

This study tests an experimental drug called HC010 in 50 people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive the drug by injection, and th…

This early-stage study tests a new treatment called NK510 for people with advanced non-small cell lung cancer (NSCLC) that no longer responds to standard immunotherapy. NK510 are natural killer cells modified to block a protein called TIGIT, which may help them attack cancer more…

This study tests whether adding a precise, high-dose radiation treatment to the liver (L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either standard dru…

This study tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemotherapy and immunotherapy can help people with advanced squamous non-small cell lung cancer live longer. About 851 adults with stage IV lung cancer will receive pembrolizumab plus chem…

This early-stage study tests a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurab…

This study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…

This early-stage study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find the safest dose and check for side effects. Participants have cancers like head and neck, lung, breast, or ovarian cancer that haven't r…

This study tests a new drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried other treat…

This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a sequence of platinum-based chemotherapy, followed by a special type of radiation (hypofractionated radiotherapy), and then the immunotherapy…

This study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The goal is to find a safe dose and see if it can shrink tumors. About 216 adults with tumors that have sp…

This study is testing an experimental drug called VT3989, taken as a pill once a day, for people with advanced solid tumors or mesothelioma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors or slow cancer gro…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study is for people with stage III non-small cell lung cancer who have already had chemotherapy and radiation. Researchers want to see if adding another drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA in the blo…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests a two-step treatment for people with advanced non-small cell lung cancer whose current targeted therapy (a third-generation EGFR TKI) has stopped working. Participants first receive chemotherapy (pemetrexed plus platinum) followed by a newer targeted drug called …

This study is for people with stage 2 to 3B lung cancer who had surgery after chemo-immunotherapy but still had cancer cells left. It tests whether adding a special immune cell treatment (L-TIL) plus another immunotherapy drug (tislelizumab) can keep the cancer from returning. Ab…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in 420 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated. The goal is to see if the new drug can delay cancer growth and extend life. …

This early-stage study tests a new drug called BBO-8520 in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the drug …

This study tests whether adding an immune-boosting vaccine (OSE2101) to a standard immunotherapy (cemiplimab) can better clear cancer DNA from the blood of people with advanced non-small cell lung cancer. About 160 participants who have not worsened after initial chemo-immunother…

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the best dose and see if the combination is safe and can…

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard first-line chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer that has spread to their bones. The goal is to improve how well the cancer respon…

This study tests a combination of experimental drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink or control tumors. About 370 participants whose cancer has worsen…

This early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …

This study tests whether combining a targeted drug (adagrasib) with precise radiation (stereotactic radiosurgery) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive …

This early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…

This study tests a new drug, EP0031, in 265 adults with advanced cancers (like lung cancer) that have a specific RET gene change. The goal is to see if the drug is safe and shrinks tumors. Participants take the drug by mouth, and doctors monitor side effects and how well it works…

This study tests whether a combination of two immunotherapy drugs (cemiplimab and fianlimab) plus radiation can shrink tumors in people with locally advanced non-small cell lung cancer who haven't had treatment before. About 76 participants will receive the drugs first, then radi…

This study looks at two types of radiation for people with 4 to 15 brain tumors that have spread from other cancers. One is a precise, short treatment called CyberKnife, and the other is whole-brain radiation given over 10 sessions. The goal is to see which approach helps patient…

This early-phase study tests a new drug called PRTH-101, alone or with pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer). The main goals are to check safety, find the best dose, and see how the drug works in the body. About 270 participants will…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …

This study looks at people with a specific type of lung cancer that has spread to the brain but isn't causing major symptoms. Half get alectinib alone, the other half get alectinib plus targeted brain radiation. The goal is to see if delaying radiation keeps the brain healthy and…

This study tests whether adding the drug BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 participants will receive both t…

This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The goal is to see if the combination is safe and shrinks tumors. Participants must …

This early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…

This study tests whether adding a local treatment (like radiation or surgery) to the targeted therapy brigatinib can better control advanced ALK-positive lung cancer. About 45 adults whose cancer has shrunk or stabilized on brigatinib alone will receive the extra treatment. The g…

This study tests whether adding two immune-boosting drugs (iparomlimab and tuvonralimab) to standard chemotherapy can shrink tumors in people with stage III lung cancer that cannot be surgically removed. About 33 adults aged 18–75 who have not had prior treatment for their cancer…

This early-phase trial tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway and have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor s…

This study tests a new drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug can shrink tumors. About 251 participants will take the drug by mouth,…

This study tests a drug called repotrectinib in people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The goal is to see if the drug can shrink or control brain tumors. About 20 adults will take the drug by mouth, and …

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase tr…

This study tests a new drug called HLX37 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth. The main goals are to check the drug's safety, find the r…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …

This early-phase trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also compare different doses in people with head and …

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study looks at how well a drug called sugemalimab works when combined with standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer (NSCLC). The study is happening in real-world clinics, not just research hospitals, and includes 150 ad…

This study compares two treatments given before surgery for stage II-IIIA non-small cell lung cancer: immunotherapy (toripalimab) plus radiation versus immunotherapy plus chemotherapy. The goal is to see which combination works better at shrinking tumors and improving surgery out…

This study tests whether adding the drug sintilimab to standard chemotherapy and a personalized radiation plan can help control stage III non-small cell lung cancer. About 35 adults aged 18-75 who cannot have surgery will receive the combination. The main goal is to see how long …

This study tests whether adding a special surgical glue (Progel Platinum) to the standard stapling method during lung cancer surgery can help patients recover faster. About 160 adults having keyhole surgery for non-small cell lung cancer will take part. The main goal is to see if…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors (including some lung cancers) that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants …

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side e…

This study is testing a new blood test called TheraSure CNI-Monitor for people with advanced lung cancer (NSCLC) who are receiving immunotherapy. The test looks for tiny bits of tumor DNA in the blood to see if the cancer is responding to treatment. Researchers want to know if th…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study looks at whether a special intermittent fasting diet can help people with advanced lung cancer who are receiving immunotherapy. Researchers want to see if the diet is safe and if it can make the cancer treatment work better. About 66 patients will take part, following …

This study looks at whether chest CT scans can help predict how well lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare CT images taken before and after treatment with actual tumor tissue removed during surgery. The goal is to develop a noni…

This study is testing whether using a breathing machine (CPAP or BiPAP) during radiation therapy can reduce tumor movement in people with advanced lung cancer, esophageal cancer, or lymphoma. The goal is to see if this approach makes radiation more accurate and reduces side effec…

This study is watching how well a treatment combining amivantamab and chemotherapy works in everyday medical practice for adults with metastatic non-small cell lung cancer that has certain EGFR gene changes. About 100 people who are already getting this treatment through an early…

This study is testing whether a computer model that looks at many types of patient data can predict how well pre-surgery treatment works for non-small cell lung cancer. Researchers will study 500 people receiving chemo-immunotherapy before surgery. The goal is to improve treatmen…

This study aims to understand how lung cancer changes when it spreads to other parts of the body. Researchers will compare DNA from the original tumor and the metastatic site in 25 adults with non-small cell lung cancer. The goal is to learn more about cancer progression, not to …

This study is for people with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body reacts to these treatments by looking for specific antibodies in the blood. The goal is to learn more about why some people respond b…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already receiving immunotherapy. Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in immune cells in the blood ca…

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …

This study is testing whether a special PET scan can predict how well a targeted cancer drug works in people with advanced lung cancer. About 50 adults with metastatic non-small cell lung cancer will get the scan before and during treatment. The goal is to see if changes in the s…

This study looks at people with early-stage lung cancer who had surgery and have no detectable tumor DNA in their blood. Half will get standard follow-up care, and the other half will have regular DNA tests and imaging instead of immediate extra treatment. The goal is to see if t…